The General Directorate of Industry, Energy and Innovation of Navarra finances with 3,7 millions different strategic R&D projects in the Biomedical area for the next three years.
These projects are: 1) Pharmanagen project, co-led by Navarrabiomed (Biomedical Research Center of the Government of Navarra and the Public University of Navarra (UPNA); 2) MINERVA project, led by CIMA and collaborating with facultatives of the Hospital of Navarre (CHN); and 3) Geneurona project, which is led by the Clínica Universidad de Navarra (CUN).
The MINERVA’s project is private public collaboration and it has been designed with a genomic approach aimed at identifying the specific molecular alterations of patients with chronic heart failure (CHF) and chronic kidney disease (CKD). The objective is to develop new biomarkers with a diagnostic utility and /or new actions with therapeutic potential that help the specialists of the Navarra Health System (SNS) and the Autonomous Community as a whole to apply a precision medicine in the context of CHF with CKD.
Ikan Biotech is delighted to participated in this project with top level and multidisciplinary partners as: Center for Applied Medical Research (CIMA), Clínica Universidad de Navarra (CUN), University of Navarra (UN) and the Hospital Complex of Navarra (CHN).
For MINERVA’s research work, the Government of Navarra has allocated a funding of 1,267,022.84 euros.